Findings support expansion of genetic testing to all women with breast cancer.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Researchers examined treatment patterns and prognostic factors in male breast cancer.
Findings remain even after adjusting for common sociodemographic factors.
Rates of grade 3/4 AEs and dose reductions/interruptions associated with CDK4/6 + AI therapy were higher in those 75 years and older compared with younger patients.